BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

NEXT STORY
BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial
PREV STORY
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding May 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") ...

author_avatar
NASDAQ Market News

Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension

WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics ...

author_avatar
NASDAQ Market News

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - ...

author_avatar
NASDAQ Market News